Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 3/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.47 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926387 | 0.91 | NAPEPLD (0.51) | NAPEPLDAKT1MAPTHTTRAB9A | |
| SCHEMBL3102408 | 0.90 | NAPEPLD (0.56) | NAPEPLDAKT1MAPTHTTPIK3CA | |
| SCHEMBL11926389 | 0.88 | NAPEPLD (0.53) | NAPEPLDMAPTRAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL11926395 | 0.88 | NAPEPLD (0.53) | NAPEPLDMAPTPIK3CA | |
| SCHEMBL11926298 | 0.85 | AKT1 (0.47) | NAPEPLDAKT1MAPTHTTRAB9A | |
| SCHEMBL11926399 | 0.85 | NAPEPLD (0.51) | NAPEPLDHTTPIK3CABRAFRAF1 | |
| SCHEMBL1271602 | 0.84 | AKT1 (0.61) | AKT1MAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL11926316 | 0.84 | NAPEPLD (0.49) | NAPEPLDAKT1MAPTHTTRAB9A | |
| SCHEMBL11926394 | 0.83 | AKT1 (0.50) | AKT1MAPTHTTRAB9ASMN1; SMN2 | |
| SCHEMBL11926307 | 0.81 | MAPT (0.52) | NAPEPLDAKT1MAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | NAPEPLD 1303/4885AKT1 1094/4885MAPT 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.